Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems
CA 2464511 A1 · Owner: Cetin, Yalcin · Inventors: Cetin, Yalcin; Savas, Yueksel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of a guanylate cyclase C activated peptide for the treatment of respiratory airway problems and problems associated with ventilation disorder and/or mucous secretion disorders via the airways in , addition to a medicament which is fed via the airways. The invention also relates to an inhalation device which contains the medicament and a method for diagnosing the illnesses associated with inhalation disorders and mucous secretion disorders in the airways, by detecting a guanylate cyclase C activated peptide. The peptides which are used are guanylin uroguanylin and , lymphoguanylin or a heat resistant enterotoxin.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 5, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 5, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 5, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.